ADMA - CIK 0001368514
The table below shows ADMA BIOLOGICS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $510.17M | $426.45M | $258.21M | $154.08M | $80.94M | $42.22M |
| Cost of revenue | $217.41M | $206.90M | $169.27M | $118.81M | $79.77M | $61.29M |
| Gross profit | $292.76M | $219.55M | $88.94M | $35.27M | $1.17M | -$19.07M |
| R&D | $4.76M | $1.81M | $3.30M | $3.61M | $3.65M | $5.91M |
ADMA BIOLOGICS, INC. reported annual revenue of $510.17M for fiscal year 2025. That is up 19.6% from $426.45M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $10.66M (FY 2016) to $510.17M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $91.58M |
| $74.12M |
| $59.02M |
| $52.46M |
| $42.90M |
| $35.05M |
| Operating income | $191.44M | $138.98M | $21.63M | -$39.37M | -$58.37M | -$64.91M |
| Income tax | $35.73M | -$71.96M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $146.93M | $197.70M | -$28.20M | -$65.90M | -$71.65M | -$75.75M |
| EPS (diluted) | $0.60 | $0.81 | -$0.13 | -$0.33 | -$0.51 | -$0.88 |